#1 Clinical Trials Search in Europe

Saccharomyces Boulardii Cncm I-745 Lyophilized

Recent clinical trials have been investigating the use of Saccharomyces Boulardii CNCM I-745 Lyophilized, a probiotic yeast, in patients undergoing antibiotic therapy. The focus is on its potential benefits for gut health, particularly in the context of early Lyme disease treatment. These studies aim to understand how this probiotic might help maintain a healthy gut microbiome and prevent antibiotic-associated side effects.

Table of Contents

What is Saccharomyces Boulardii CNCM I-745?

Saccharomyces Boulardii CNCM I-745 is a specific strain of yeast that is used as a probiotic. It is also known by its brand name Enterol 250 mg[1]. This probiotic is classified as an antidiarrheal medication and is used to help maintain a healthy balance of bacteria in your gut, especially when you’re taking antibiotics[1].

How It Works

When you take antibiotics, they can kill both harmful and beneficial bacteria in your gut. This can disrupt your normal gut flora, potentially leading to digestive issues. Saccharomyces Boulardii CNCM I-745 works by:

  • Helping to maintain a healthy balance of microorganisms in your intestines
  • Supporting your gut’s natural defense mechanisms
  • Potentially reducing the risk of antibiotic-associated diarrhea (AAD)

This probiotic is particularly useful for patients who are undergoing antibiotic therapy, such as those being treated for erythema migrans, which is an early skin manifestation of Lyme disease[1].

Benefits for Patients on Antibiotic Therapy

Research suggests that Saccharomyces Boulardii CNCM I-745 may offer several benefits for patients taking antibiotics:

  1. Prevention of antibiotic-associated diarrhea (AAD): It may help reduce the likelihood of developing diarrhea as a side effect of antibiotic use[1].
  2. Improved stool consistency: The probiotic may help maintain normal stool consistency during antibiotic treatment[1].
  3. Protection of gut microbiota: It may help preserve the diversity of beneficial bacteria in your gut, which can be affected by antibiotics[1].
  4. Reduction of gastrointestinal symptoms: It may help alleviate other digestive symptoms that can occur during antibiotic treatment[1].

Usage and Dosage

Based on the clinical trial information, the typical dosage of Saccharomyces Boulardii CNCM I-745 is:

  • 500 mg twice daily (1000 mg total per day)
  • Taken for 21 days, starting at the same time as antibiotic treatment

It’s important to note that this dosage is specific to the clinical trial and may differ from general usage guidelines. Always follow your healthcare provider’s instructions or the directions on the product label[1].

Safety and Side Effects

Saccharomyces Boulardii CNCM I-745 is generally considered safe for most people. However, as with any medication or supplement, there are some precautions to be aware of:

  • It should not be used by people with known hypersensitivity to yeast products
  • It’s not recommended for people with severe liver or kidney problems
  • It should be used with caution in immunocompromised individuals or those with central venous catheters

The clinical trial is also assessing the safety and tolerability of this probiotic, which will provide more information about potential side effects[1].

Ongoing Research

A clinical trial (SUBLYME) is currently underway to further investigate the effects of Saccharomyces Boulardii CNCM I-745 in patients receiving antibiotic therapy for early Lyme disease. The study aims to:

  • Assess how the probiotic affects gut microbiota during antibiotic treatment
  • Evaluate its effectiveness in preventing antibiotic-associated diarrhea
  • Examine its impact on stool consistency and other gastrointestinal symptoms
  • Investigate its effects on the gut’s resistance to harmful bacteria (gut resistome)

This research will provide valuable insights into the benefits of using Saccharomyces Boulardii CNCM I-745 alongside antibiotic treatment, particularly for patients with early Lyme disease[1].

Aspect Details
Study Drug Saccharomyces Boulardii CNCM I-745 Lyophilized
Medical Condition Patients undergoing antibiotic therapy for early Lyme disease (erythema migrans)
Main Objective Assess effect on gut microbiota during antibiotic therapy
Secondary Objectives Prevent antibiotic-associated diarrhea, assess stool consistency, evaluate safety and tolerability
Study Design Placebo-controlled, double-blind, parallel-group
Treatment Groups 1) Antibiotics + Saccharomyces boulardii, 2) Antibiotics + Placebo
Duration 21 days of probiotic/placebo treatment
Key Measurements Changes in gut microbiota diversity, incidence of diarrhea, stool consistency, gastrointestinal symptoms

FAQ

  • What is Saccharomyces Boulardii CNCM I-745? Saccharomyces Boulardii CNCM I-745 is a specific strain of probiotic yeast. It's used to help maintain healthy gut flora, especially during antibiotic treatment.
  • Why is this probiotic being studied with antibiotic therapy? The probiotic is being studied to see if it can help protect the gut microbiota during antibiotic treatment, potentially reducing side effects like antibiotic-associated diarrhea.
  • What are the main objectives of the clinical trial? The main objectives are to assess how Saccharomyces Boulardii CNCM I-745 affects gut microbiota, its effectiveness in preventing antibiotic-associated diarrhea, and its impact on stool consistency in patients taking antibiotics.
  • Who can participate in this clinical trial? Adult patients (18 years or older) who have been prescribed antibiotic therapy for early Lyme disease (erythema migrans) can participate, provided they meet other specific health criteria.
  • How is the probiotic administered in the trial? In the trial, patients receive either Saccharomyces Boulardii CNCM I-745 500 mg twice daily for 21 days along with antibiotics, or antibiotics with a placebo.

Ongoing Clinical Trials on Saccharomyces Boulardii Cncm I-745 Lyophilized

  • Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal Spain

  • Study on the Effects of Saccharomyces boulardii CNCM I-745 and Amoxicillin on Gut Health in Patients with Early Lyme Disease Undergoing Antibiotic Treatment

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Lithuania Slovakia Slovenia

Glossary

  • Saccharomyces Boulardii CNCM I-745: A specific strain of probiotic yeast used to support gut health, especially during antibiotic treatment.
  • Erythema Migrans: An expanding red rash that is often the first sign of Lyme disease, typically appearing at the site of a tick bite.
  • Antibiotic-Associated Diarrhea (AAD): Diarrhea that occurs as a side effect of taking antibiotics, often due to disruption of the normal gut bacteria.
  • Gut Microbiota: The community of microorganisms living in the digestive tract, playing crucial roles in health and digestion.
  • Probiotic: Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
  • Bristol Stool Form Scale (BSFS): A medical aid designed to classify the form of human feces into seven categories, used to assess stool consistency.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind Study: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Gut Resistome: The collection of all antibiotic resistance genes in the gut microbiome.
  • Alpha Diversity: A measure of the variety of species within a single sample or community.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-saccharomyces-boulardii-cncm-i-745-and-amoxicillin-on-gut-health-in-patients-with-early-lyme-disease-undergoing-antibiotic-treatment/